Kodiak Sciences Inc. (KOD) stock forecast & analysis
87.79
NasdaqGM · USD
Down: -2.13, -2.4%
1 analysis
- Open
- 87.50
- Previous close
- 89.92
- Day range
- 83.64 – 93.14
- 52-week range
- 10.94 – 95.77
- Volume (shares)
- 1.87M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 62.85M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 2.18
- Market cap
- 5.52B
Market Scanner’s AI analysis of Kodiak Sciences Inc. (KOD), updated September 2026: Kodiak Sciences' stock surged on positive Phase III trial results for AMD drug candidates, outpacing market trends.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Kodiak Sciences Inc. (KOD) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Kodiak Sciences' stock surged on positive Phase III trial results for AMD drug candidates, outpacing market trends.
Recent analyses covered Kodiak Sciences' (KOD) significant stock price increase, driven by positive Phase III trial results for its wet age-related macular degeneration (AMD) drug candidates, Zenkuda and tabirafusp-ted. The market analyst report detailed extremely bullish technical indicators, including substantial price appreciation above key moving averages and high momentum readings. The fundamentals analyst report noted the company's market capitalization, profitability metrics, and liquidity position.
KOD news & sentiment
News reports highlighted a significant stock surge for Kodiak Sciences following positive clinical trial results for its AMD drug candidates. Market sentiment showed caution due to macroeconomic factors, though KOD's specific news drove it to a 52-week high.
KOD technical picture
The stock exhibited extreme positive momentum and significant price appreciation, trading substantially above its 50-day and 200-day simple moving averages. Momentum indicators, including the Relative Strength Index and Money Flow Index, showed extremely high readings, confirming robust buying pressure and capital inflow.
Fundamentals
The company has a substantial market capitalization and a healthy short-term liquidity position, indicated by its current and quick ratios. However, it reported negative earnings per share and return on equity on a trailing twelve months basis, alongside significant debt.
Factors discussed — upside
- Positive Phase III trial results for Zenkuda and tabirafusp-ted met primary endpoints.
- Extreme positive momentum indicated by technical indicators (RSI, MFI).
- Stock price trading substantially above 50-day and 200-day SMAs.
- Healthy short-term liquidity position with a Current Ratio of 2.489 and Quick Ratio of 2.386.
- Company positioned as a competitor to Regeneron Pharmaceuticals in the AMD drug market.
Factors discussed — risks
- Negative Earnings Per Share (EPS) of -4.19 on a trailing twelve months basis.
- Return on Equity (ROE) of -368.4% on a trailing twelve months basis.
- High stock volatility with a Beta of 2.18.
- Broader market sentiment showing caution due to rising bond yields and AI developments.
- Biotechnology drug development
- Clinical trial results
- Technical analysis
- Financial health
Summary updated .
KOD technical indicators
Common technical indicators for KOD, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 40.34 | Price above |
| 10-day exponential moving average | 51.46 | Price above |
| Relative strength index (14-day) | 86.89 | Overbought |
| MACD line (12/26/9) | 6.3565 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 6.13 – 72.50 | Price above the upper band |
Analyses
Recent KOD.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Kodiak Sciences Inc.?
- The bull case centers on positive Phase III trial results for the company's AMD drug candidates, Zenkuda and tabirafusp-ted, which met primary endpoints and positioned KOD as a competitor to Regeneron Pharmaceuticals. Technical indicators show extreme positive momentum and significant price appreciation above key moving averages, supported by healthy short-term liquidity.
- What are the risks for Kodiak Sciences Inc.?
- Risks highlighted include negative trailing twelve months EPS and ROE figures, alongside high stock volatility indicated by a Beta of 2.18. The company also faces broader market headwinds influenced by rising bond yields and AI developments.
- Is Kodiak Sciences Inc. bullish or bearish?
- Recent AI analyses of Kodiak Sciences Inc. examined factors on both sides. Discussed upside: The bull case centers on positive Phase III trial results for the company's AMD drug candidates, Zenkuda and tabirafusp-ted, which met primary endpoints and positioned KOD as a competitor to Regeneron Pharmaceuticals. Technical indicators show extreme positive momentum and significant price appreciation above key moving averages, supported by healthy short-term liquidity. Discussed risks: Risks highlighted include negative trailing twelve months EPS and ROE figures, alongside high stock volatility indicated by a Beta of 2.18. The company also faces broader market headwinds influenced by rising bond yields and AI developments. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Kodiak Sciences Inc.?
- News reports highlighted a significant stock surge for Kodiak Sciences following positive clinical trial results for its AMD drug candidates. Market sentiment showed caution due to macroeconomic factors, though KOD's specific news drove it to a 52-week high.
- How does Market Scanner analyse Kodiak Sciences Inc.?
- Every analysis of Kodiak Sciences Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh KOD.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.